UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Annals of oncology, 2016-10, Vol.27, p.vi328-vi328

2016

Volltextzugriff (PDF)

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S108-S108

2015

Volltextzugriff (PDF)

Immunomodulating Cytokines May Improve Overall Survival Prediction After Radiation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S669-S670

2014

Volltextzugriff (PDF)

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S69-S69

2015

Volltextzugriff (PDF)

A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data

Annals of oncology, 2014-09, Vol.25, p.iv365

2014

Volltextzugriff (PDF)

Inhibition of Cyclin D-CDK4/CDK6 Activity is Associated with an E2F-Mediated Induction of Cyclin Kinase Inhibitor Activity

Proceedings of the National Academy of Sciences - PNAS, 1996-04, Vol.93 (9), p.4350-4354

1996

Volltextzugriff (PDF)

S16 Tumor biomarkers, the need for a new way to conduct business. Perspective from the US FDA

European journal of cancer supplements, 2007, Vol.5 (8), p.11-11

Khleif, S

2007

Volltextzugriff (PDF)

Jordan Palliative Care Initiative: A WHO Demonstration Project

Journal of pain and symptom management, 2007-05, Vol.33 (5), p.628-633

2007

Volltextzugriff (PDF)

Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1848-1854

2001

Volltextzugriff (PDF)

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors

Journal of immunotherapy, 1999-03, Vol.22 (2), p.155-165

1999

Volltextzugriff (PDF)

Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding

Oncogene, 1997-03, Vol.14 (10), p.1243-1248

1997

Volltextzugriff (PDF)

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi421-vi421

2016

Volltextzugriff (PDF)

Mechanisms of Tumor Evasion

Cancer treatment and research, 2005, Vol.123, p.61-88

2005

Volltextzugriff (PDF)

Incomplete Penetrance of Familial Retinoblastoma Linked to Germ-Line Mutations that Result in Partial Loss of RB Function

Proceedings of the National Academy of Sciences - PNAS, 1997-10, Vol.94 (22), p.12036-12040

1997

Volltextzugriff (PDF)

Antibody Inducing Polyvalent Cancer Vaccines

Cancer treatment and research, 2005, Vol.123, p.157-180

2005

Volltextzugriff (PDF)

1325PCLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) ANTIBODY, IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv466-iv466

2014

Volltextzugriff (PDF)

Clinical Activity and Safety of Medi4736, an Anti-Programmed Cell Death-Ligand 1 (Pd-L1) Antibody, in Patients with Non-Small Cell Lung Cancer

Annals of oncology, 2014-09, Vol.25, p.iv466

2014

Volltextzugriff (PDF)

Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway

Cancer immunology research, 2014-11, Vol.2 (11), p.1080-1089

2014

Volltextzugriff (PDF)

Tumor Antigens and Tumor Antigen Discovery

Cancer treatment and research, 2005, Vol.123, p.89-111

2005

Volltextzugriff (PDF)

1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv365-iv365

2014

Volltextzugriff (PDF)

Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex

Journal of Virology, 1996-08, Vol.70 (8), p.5503-5510

1996

Volltextzugriff (PDF)

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations

Cellular immunology, 1997-12, Vol.182 (2), p.137-151

1997

Volltextzugriff (PDF)

Tumor Immunology and Cancer Vaccines

1, 2005

Volltextzugriff (PDF)

The role of vaccines in cancer prevention

Cancer treatment and research, 2001, Vol.106, p.283

2001

Volltextzugriff (PDF)

1 – 25 von 399

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(287)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

Immunomodulating Cytokines May Improve Overall Survival Prediction After Radiation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer

346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

A Phase I Multi-Arm Dose-Expansion Study of the Anti-Programmed Cell Death-Ligand-1 (Pd-L1) Antibody Medi4736: Preliminary Data

Inhibition of Cyclin D-CDK4/CDK6 Activity is Associated with an E2F-Mediated Induction of Cyclin Kinase Inhibitor Activity

S16 Tumor biomarkers, the need for a new way to conduct business. Perspective from the US FDA

Jordan Palliative Care Initiative: A WHO Demonstration Project

Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors

Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

Mechanisms of Tumor Evasion

Incomplete Penetrance of Familial Retinoblastoma Linked to Germ-Line Mutations that Result in Partial Loss of RB Function

Antibody Inducing Polyvalent Cancer Vaccines

1325PCLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) ANTIBODY, IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Clinical Activity and Safety of Medi4736, an Anti-Programmed Cell Death-Ligand 1 (Pd-L1) Antibody, in Patients with Non-Small Cell Lung Cancer

Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway

Tumor Antigens and Tumor Antigen Discovery

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015

1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA

Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations

Tumor Immunology and Cancer Vaccines

The role of vaccines in cancer prevention

Suchergebnisse filtern